Bibliometric analysis of global research on breast cancer with HER2-low expression

Junpeng Zhu, Jin Hu, Lei Hao, Runze Li, Yu Zhao, Yaqi Zhao, Hengyu Chen, Lei Li, Chong Lu, Chunping LiuDiscover 2025 · DOI

TL;DR

This paper uses bibliometric analysis to map the rapidly growing global research landscape of HER2-low breast cancer, a subtype that has gained significant attention since its formal definition in 2018. The study identifies key countries, institutions, authors, and research themes, highlighting the shift towards targeted therapies like antibody-drug conjugates (ADCs) and the increasing focus on diagnostic standardization and clinical trial outcomes.

What Problem Does This Paper Address?

Breast cancer is a major global health concern, and its classification has historically relied on hormone receptor (HR) and HER2 expression. While HER2-positive and HER2-negative were the primary categories, a significant portion of breast cancers (around 45-55%) exhibit low HER2 expression (IHC 1+ or 2+ with negative ISH). This "HER2-low" category, formally defined by ASCO-CAP guidelines in 2018, presents distinct molecular and clinical characteristics, and importantly, has emerged as a promising target for novel therapies, particularly antibody-drug conjugates (ADCs). However, the explosion of research in this area necessitates a structured overview to understand its trajectory, identify key players, and pinpoint emerging trends. This paper addresses this need by providing a comprehensive bibliometric analysis of the global research output on HER2-low breast cancer.

Methods

The researchers employed a bibliometric approach, utilizing data from the Web of Science Core Collection (WoSCC) database. They searched for articles published between January 2018 and March 2025 using specific keywords related to "breast neoplasm" or "breast cancer" and "HER2-low" or "ERBB2-low." To ensure data quality and relevance, the search was refined to include only original research articles and reviews written in English. The analysis involved several bibliometric tools:

  • Bibliometrix R package: Used for comprehensive science mapping and thematic analysis.
  • VOSviewer: Employed for visualizing network relationships between countries, institutions, authors, and keywords, with node size representing frequency and link thickness indicating association strength.
  • CiteSpace: Utilized for generating specialized visualizations such as keyword timeline maps, keyword burst detection maps, and dual-map overlays of journal citation networks, helping to identify research hotspots and evolution over time.

The analysis focused on publication volume, country and institutional contributions, author impact, journal influence, and keyword trends.

Datasets

The primary dataset for this study was derived from the Web of Science Core Collection (WoSCC) database. The search was conducted for articles published between January 2018 and March 2025. After initial retrieval and duplicate removal, a total of 573 documents were included in the analysis. No new benchmarks or datasets were introduced by the authors; rather, they analyzed existing published literature.

Key Insights and Ideas

  • The "HER2-low" revolution is real and rapidly growing: The formal definition in 2018 has catalyzed a significant surge in research, with a notable increase in publications, particularly in 2023. This indicates a paradigm shift in breast cancer research.
  • ADCs are the driving force: The emergence and success of antibody-drug conjugates (ADCs), especially Trastuzumab Deruxtecan (T-DXd), have fundamentally reshaped the HER2-low landscape, shifting research focus from basic characterization to therapeutic applications and outcomes.
  • Global collaboration is emerging, but with distinct hubs: While research is global, China and the United States are leading in publication volume, with strong contributions from Italy. International collaboration is present but appears to be strongest between specific countries.
  • Keywords reveal a dynamic research focus: The research emphasis has evolved from initial terms like "antibody-drug conjugates" and "clinical trials" to more recent keywords such as "prognostic factor," "immunohistochemistry," "overall survival," and "pathological complete response," reflecting a maturation of the field.

Key Results

  • Publication Trend: A steady increase in publications since 2018, with a significant surge in 2023. Projections suggest over 250 publications in 2025.
  • Top Contributing Countries: China (210 publications) and the USA (184 publications) are the leading contributors, followed by Italy (100 publications).
  • Leading Institutions: Harvard University (47 publications), University of Milan (45 publications), and UNICANCER (40 publications) are at the forefront.
  • Influential Authors: Giuseppe Curigliano is identified as the most prolific author with 27 publications.
  • Key Journals: CANCERS and FRONTIERS IN ONCOLOGY are top journals for literature sources, while JOURNAL OF CLINICAL ONCOLOGY and NEW ENGLAND JOURNAL OF MEDICINE lead in citation counts.
  • Most Cited Literature: The highly cited works revolve around Trastuzumab Deruxtecan and the pathological and clinical landscape of HER2-low breast cancer.
  • Keyword Evolution: A clear shift from early terms like "antibody-drug conjugates" to later terms like "prognostic factor," "immunohistochemistry," and "overall survival."

Limitations and Future Work

The authors acknowledge several limitations:

  • Database Selection Bias: Relying solely on WoSCC may exclude relevant research from other databases.
  • Citation-Age Effects: The analysis might underestimate emerging trends due to citation lag.
  • Language Restriction: Excluding non-English articles may miss valuable research.
  • Starting Point: While 2018 was chosen due to the ASCO/CAP guideline update, this might miss pre-2018 studies that retrospectively fit the HER2-low definition (though a manual review suggested few such papers).
  • Article Type Restriction: Limiting to articles and reviews might exclude other relevant publication types.
  • Low Citation Rate Bias: Recent high-quality articles with low citation rates might not have a significant impact on the analysis.

Future work should focus on:

  • Elucidating microenvironmental drivers of HER2 expression dynamics.
  • Developing ctDNA-based multigene panel testing for real-time HER2 status monitoring.
  • Investigating resistance mechanisms to ADCs and developing next-generation ADCs.
  • Fostering collaboration between clinical practice and research, particularly in Low- and Middle-Income Countries (LMICs), to improve access to diagnostics and novel therapies.
  • Establishing standardized diagnostic criteria and quality assurance for HER2 testing.

Summary updated

Abstract

This study applies bibliometric tools to analyze the literature on HER2-low expression breast cancer, which shows a notable upward trend and highlights the clinical significance, providing researchers with the priorities and hotspots in this crucial field.
BibTeX
@inproceedings{zhu2025bibliometric,
  author = {Junpeng Zhu and Jin Hu and Lei Hao and Runze Li and Yu Zhao and Yaqi Zhao and Hengyu Chen and Lei Li and Chong Lu and Chunping Liu},
  title = {{Bibliometric analysis of global research on breast cancer with HER2-low expression}},
  booktitle = {Discover},
  year = {2025},
  doi = {10.1007/s12672-025-03820-5},
}
Figure